The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number
Open Access
- 10 June 2010
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 115 (23), 4671-4677
- https://doi.org/10.1182/blood-2010-01-256958
Abstract
The reduced folate carrier (RFC) is involved in the transport of methotrexate (MTX) across the cell membrane. The RFC gene (SLC19A1) is located on chromosome 21, and we hypothesized that the RFC80 G>A polymorphism would affect outcome and toxicity in childhood leukemia and that this could interact with chromosome 21 copy number in the leukemic clone. A total of 500 children with acute lymphoblastic leukemia treated according to the common Nordic treatment protocols were included, and we found that the RFC AA variant was associated with a 50% better chance of staying in remission compared with GG or GA variants (P = .046). Increased copy numbers of chromosome 21 appear to improve outcome also in children with GA or GG variant. In a subset of 182 children receiving 608 high-dose MTX courses, we observed higher degree of bone marrow toxicity in patients with the RFC AA variant compared with GA/GG variants (platelet 73 vs 99/105 × 109/L, P = .004, hemoglobin 5.6 vs 5.9/6.0 mmol/L, P = .004) and a higher degree of liver toxicity in patients with RFC GG variant (alanine aminotransferase 167 vs 127/124 U/L, P = .05). In conclusion, the RFC 80G>A polymorphism interacts with chromosome 21 copy numbers and affects both efficacy and toxicity of MTX.Keywords
This publication has 31 references indexed in Scilit:
- Advances in individual prediction of methotrexate toxicity: a reviewBritish Journal of Haematology, 2009
- Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemiaBlood, 2009
- Outcome of ETV6/RUNX1‐positive childhood acute lymphoblastic leukaemia in the NOPHO‐ALL‐1992 protocol: frequent late relapses but good overall survivalBritish Journal of Haematology, 2008
- Reduced folate carrier polymorphism determines methotrexate uptake by B cells and CD4+ T cellsRheumatology, 2007
- High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemiaLeukemia, 2006
- Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritisArthritis & Rheumatism, 2004
- Continuing therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanineCancer Treatment Reviews, 2001
- Molecular and Cellular Correlates of Methotrexate Response in Childhood Acute Lymphoblastic LeukemiaLeukemia & Lymphoma, 1999
- The Pharmacology and Clinical Use of MethotrexateThe New England Journal of Medicine, 1983
- The clinical pharmacology of methotrexateCancer Treatment Reviews, 1983